Drug Trial Radar · NCT06279793
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Feb 15, 2024
Primary completion
Mar 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- GCP-Service International West GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- University Hospital, Bonn; University Hospital Muenster; University Hospital Goettingen; Charite University, Berlin, Germany; Wuerzburg University Hospital; Johannes Gutenberg University Mainz; University Hospital Augsburg; Universitätsklinikum Hamburg-Eppendorf; University Medical Center Rostock; University Hospital Schleswig-Holstein; Robert Bosch-Krankenhaus Stuttgart
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.
Conditions
- Intensive Care Unit
- Coronary Artery Bypass Grafting (CABG)
- High Risk Patients
- Cardiopulmonary Bypass
- Elective Cardiac Surgery
- Valvular Heart Surgery
- Multiple Valve Surgeries
- Combined Cardiac Procedures
- Aortic Surgical Procedures
- Adult Patients ≥ 18 Years
- Combined Valve and CABG
- Combined Cardiac and Aortic Surgical Procedures
Interventions
Fish OilDrug
Omegaven® is a 10% fish oil emulsion with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids. Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose. Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL). Timeframe: Day -1: 0.20 g fish oil/kg BW/d (the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion); intraoperative day 0: no dose; postoperative day 0: 0.20 g fish oil/kg BW/d; postoperative days 1 to max. 7): 0.20 g fish oil/kg BW/d
Intravenous 0.9% Sodium ChlorideDrug
Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d) provided at the same timepoints as the intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Atrial fibrillationTime frame: Postoperative days 0-7
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Augsburg
Augsburg, Germany · Recruiting
Charité Universitätsmedizin Berlin
Berlin, Germany · Recruiting
University of Bonn
Bonn, Germany · Recruiting
University Hospital Goettingen
Göttingen, Germany · Recruiting
University Hospital Hamburg-Eppendorf
Hamburg, Germany · Recruiting
University Medical Center Schleswig-Holstein
Kiel, Germany · Recruiting
University Hospital Mainz
Mainz, Germany · Recruiting
University Hospital Muenster
Münster, Germany · Recruiting
University Medical Center Rostock
Rostock, Germany · Not yet recruiting
Robert Bosch Medical Center
Stuttgart, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.